Business Context and Reporting Period
This Form 8-K is filed by Fluidigm Corporation (not Standard BioTools Inc.) on February 21, 2019, reporting events occurring between February 14, 2019 and February 20, 2019. The filing addresses voluntary conversions of the Company's 2.75% Exchange Convertible Senior Notes due 2034.
Key Financial Metrics
- Debt Reduction: The Company retired $54,858,000 in aggregate principal amount of Senior Convertible Notes.
- Total Retired Debt: Cumulative principal amount of Senior Convertible Notes retired as of February 20, 2019, reached $131,498,000.
- Equity Issuance: The Company delivered 7,115,778 shares of common stock to satisfy conversion obligations.
- Share Count: Post-settlement, the Company has approximately 66.5 million shares of common stock outstanding.
- Revenue, Profit, Cash Flow, Margins, Liquidity: The filing text does not provide a clear value for these metrics.
Material Changes
The primary material change is the reduction of outstanding debt and the corresponding increase in outstanding common stock due to the voluntary conversion of approximately $54.9 million in Senior Convertible Notes. This transaction was executed pursuant to the Second Supplemental Indenture dated March 6, 2018.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or specific risk factors beyond the execution of the debt conversion. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the updated total outstanding principal of the 2.75% Senior Convertible Notes due 2034.
- Confirm the exact number of shares outstanding post-conversion (approx. 66.5 million) and its impact on dilution.
- Review the Second Supplemental Indenture dated March 6, 2018, to understand the terms governing these voluntary conversions.
- Check subsequent filings for any impact on the Company's liquidity position resulting from the equity settlement.